@BioValues From May 15 10Q: we paused further enrollment in our ongoing Phase 1 study of BA3182 (CAB-EpCAM x CAB-CD3), while continuing treatment, follow-up of patients, including obtaining new scans in the study.
$BTQ PR dense w/ nada - separate link below to unearth detailed pathetic financials.
https://t.co/63NolzZrTi
Remember financials in Canadian dollars - converts to only $28M USD cash + lost $6.4M USD in Q yet says cash "multi-year runway" which suggests how little invest in R&D.
@EpochSwing Details coming..."Jazz (ZYME's partner) plans to submit these data for presentation at a major medical meeting in the first quarter of 2026 and for publication in a peer-reviewed journal" $ZYME $JAZZ
@ValueForAll1 "Market" Keyword search for 11/10 10Q and did not find your info. Please paste the exact language. TY
I did find "Subsequent to September 30, 2025, the Company received $52.1 million in net proceeds under its βat-the-marketβ equity program." The earns PR said $72.1M #WVE
$AVXL Somewhat more EMA timeline clarity during Q+A.
On previous Q call said EMA decision would be eoy or early Q1; Now says "probably first quarter next year".
Also said during cc would only seek a partner if EMA approval granted.
@avidresearch Post referenced by avid
$SPRO milestone reduction fr $150M to $101M on 1st sales makes total sense + is non-event bec payment is detemined by trial cost; when trial stopped early for efficacy, expenses went down by about $50M due to far fewer pts in ph 3 trial than orig thought.
$SPRO milestone reduction fr $150M to $101M on 1st sales makes total sense + should be interpreted as a non-event bec payment is detemined by trial cost; when trial stopped early for efficacy, expenses went down by about $50M due to far fewer pts in ph 3 trial than orig thought.